CONFERENCE PROGRAM

From Concept to the Clinic

November 14 – 16, 2017

Joseph B. Martin Conference Center, Harvard Medical School
77 Avenue Louis Pasteur, Boston, MA 02115
President’s Message

Dear Colleague:

“The standard of care is just not good enough,” Michael Pellini, M.D., Chairman, Board of Directors, Foundation Medicine, told the audience at the 12th Annual Personalized Medicine Conference. It is time, Pellini said, to think about the space differently.

Guided by that premise, the 13th Annual Personalized Medicine Conference will facilitate dialogue focused on translating the concept of personalized medicine into improved clinical care. Participants will engage with thought leaders and health professionals from the front lines to explore, among other subjects, how an under-studied value proposition, information technology challenges and practical obstacles at the point of care complicate efforts to bring personalized medicine to patients — and how emerging partnership models, economic utility studies and real-world evidence may help to eliminate these impediments. The agenda includes:

- An exploration of the implications of CRISPR-Cas9 and gene therapy for medicine and humanity
- A fireside chat with a pharmaceutical industry representative on the pricing of personalized medicines
- A discussion of case studies on the economic value of personalized medicine
- Detailed clinical insights from patients, providers and payers

I hope you will join your colleagues from the industry, policy, payer, clinician and patient communities to help us chart a course for the future of personalized medicine by participating in the program, which will explore the evolution of personalized medicine “From Concept to the Clinic.”

Sincerely yours,

Edward Abrahams, Ph.D.
President
Personalized Medicine Coalition
The 13th Annual Personalized Medicine Conference will begin with informal discussions on the field and its future during a welcome reception at the Hotel Commonwealth at 5:30 p.m. ET on November 14.

NOVEMBER 14, 2017

Hotel Commonwealth
500 Commonwealth Ave.
Boston, MA 02215
“It’s not really ‘should we do this.’ We have to do this. We don’t get to decide what the biology of these diseases are, we just have to work with it.”

Barbara Weber, M.D.
Venture Partner, Third Rock Ventures
7:00 a.m. | Registration and Breakfast

8:00 a.m. | Opening Remarks

  SPEAKER | Edward Abrahams, Ph.D., President, Personalized Medicine Coalition

8:10 a.m. | The State of Personalized Medicine

  INTRODUCTION | Steven D. Averbuch, M.D., Head, Precision Medicine, R & D, Bristol-Myers Squibb

  KEYNOTE | Thomas J. Lynch, Jr., M.D., Executive Vice President, Chief Scientific Officer, R & D, Bristol-Myers Squibb

8:40 a.m. | 13th Annual Leadership in Personalized Medicine Award

  PRESENTER | Kimberly Popovits, Chairman of the Board, CEO, President, Genomic Health

  AWARDEE | Jay T. Flatley, Executive Chairman, Illumina

9:10 a.m. | Networking Break

9:35 a.m. | Progress in Partnerships: A Two-Part Discussion

  Aligning the constructs of the health system with the principles of personalized medicine will require stakeholders to scale the most promising cross-sector partnership models. This series of fireside chats will examine the potential of two such models.

  9:45 A.M. | A Model for Risk-Sharing Agreements Between Payers and the Pharmaceutical Industry

  Many payers are reluctant to assume that covering personalized medicines will help mitigate costs associated with catastrophic medical events that require hospitalization. During this fireside chat, representatives from Amgen and Harvard Pilgrim Health Care will discuss the logic and implications of their groundbreaking agreement to share the financial risks of covering a targeted medicine based on that premise. Under the terms of the agreement, Amgen agreed to cover treatment costs for patients who have a heart attack or stroke while taking its personalized therapy for familial hypercholesterolemia.

  MODERATOR | Meg Tirrell, M.S.J., Reporter, CNBC

Joshua Ofman, M.D., M.S.H.S., Senior Vice President, Global Value, Access & Policy, Amgen Inc.

Michael Sherman, M.D., M.B.A., M.S., Senior Vice President, Chief Medical Officer, Harvard Pilgrim Health Care

10:15 A.M. | A Model for Universal Companion Diagnostic Agreements Between Diagnostic Companies and the Pharmaceutical Industry

  The advent of next-generation sequencing has the potential to revolutionize health care by unlocking an era in which doctors can use a single test to assess which of several treatment regimens is most appropriate for a given patient. During this fireside chat, representatives from Novartis, Pfizer and Thermo Fisher Scientific will discuss their pioneering work in developing the first of these “universal companion diagnostics” to receive FDA approval – an effort that reinvented the traditional “one drug, one test” model.

  MODERATOR | Alexander Vadas, Ph.D., Managing Director, L.E.K. Consulting

Joydeep Goswami, Ph.D., President, Clinical Next-Generation Sequencing, Oncology, Thermo Fisher Scientific

Anne-Marie Martin, Ph.D., Senior Vice President, Global Head of Precision Medicine, Novartis (invited)

Hakan Sakul, Ph.D., Vice President, Head of Diagnostics, Genome Sciences & Technologies, Worldwide R&D, Pfizer
10:35 a.m. Real-World Personalized Medicine: Examining the Role of Real-World Evidence in Personalizing Health Care

FDA has offered a definition of real-world evidence, but the community continues to debate what is needed to fully integrate it into decision-making. This session will explore what real-world evidence is, how it is being used and what regulatory requirements are needed to realize its potential.

MODERATOR | Amy Abernethy, M.D., Ph.D., Chief Medical Officer, Senior Vice President, Oncology, Flatiron Health
Sean Khozin, M.D., M.P.H., Associate Director (Acting), Oncology Center of Excellence, FDA
Eric G. Klein, Pharm.D., Senior Director, Oncology, Global Patient Outcomes and Real World Evidence, Eli Lilly and Company
Maria Koehler, M.D., Ph.D., Vice President, Oncology Strategy, Innovation and Collaborations, Pfizer Oncology
Deborah Schrag, M.D., M.P.H., Chief, Division of Population Sciences, Medical Oncology, Dana-Farber Cancer Institute

11:50 a.m. Luncheon

1:00 p.m. The Designer Genome: Exploring the Implications of Gene Editing and Gene Therapy for the Future of Medicine and Humanity

Many scientists believe the regularly interspaced short palindromic repeats (CRISPR-Cas9) genetic engineering tool and recent developments in gene therapy will dramatically alter the trajectory of medicine, but the implications of these developments for health systems around the world remain unclear. During this session, a panel of experts will discuss the status of these new technologies — and how the medical community and regulatory agencies may have to adapt to keep up with forthcoming developments.

MODERATOR | Kevin Davies, Ph.D., Co-Author, DNA: The Story of the Genetic Revolution (with Jim Watson & Andrew Berry); Executive Editor, The CRISPR Journal
Katrine Bosley, CEO, Editas Medicine
Arthur L. Caplan, Ph.D., Drs. William F. and Virginia Connolly Mitty Chair; Director, Division of Medical Ethics, New York University Langone Medical Center
George Church, Ph.D., Professor of Genetics, Health Sciences, Technology, Harvard and MIT; Director of HMS NHGRI-Center of Excellence in Genomic Science; Director of the Personal Genome Project, Broad Institute & Wyss Harvard Institute of Biologically Inspired Engineering Harvard Medical School
Jeffrey D. Marrazzo, M.B.A., M.P.A., Co-Founder, CEO, Spark Therapeutics

2:15 p.m. Pricing Personalized Medicines

The increasing pressure on industry stakeholders to alter their drug pricing practices has particular significance for personalized medicines, which must recoup research and development costs from smaller patient populations. This conversation will explore the pharmaceutical industry’s strategies for facilitating patient access to these therapies.

MODERATOR | Meg Tirrell, M.S.J., Reporter, CNBC
Stephen J. Ubl, President, CEO, PhRMA

2:45 p.m. Networking Break
(sponsored by GreyBird Ventures)
3:15 p.m.  
**Precision Valuation: A Discussion of How Value Assessment Frameworks Can Account for Personalized Medicine**

Payers control access to personalized medicine, and some have begun to take an interest in findings from value assessment frameworks that are challenged to account for scientific developments in the field. In addition to exploring their potential impact on individualized care, this session will examine how value assessment frameworks can and should consider personalized medicine as part of their processes for evaluating therapeutic options.

**MODERATOR | Jennifer Snow, M.P.H., Director, Health Policy, Xcenda**

**Dane J. Dickson, M.D., CEO, Cure-One (formerly MED-C); Director, Precision Medicine Policy and Registries, Knight Cancer Center at OHSU**

**Robert Dubois, M.D., Ph.D., Chief Science Officer, Executive Vice President, National Pharmaceutical Council**

**Andrea Ferris, M.B.A., President, Chairman of the Board, LUNGevity Foundation**

**Steven Pearson, M.D., M.Sc., Founder, President, Institute for Clinical and Economic Review (ICER)**

4:30 p.m.  

Although personalized medicine's proponents contend that the field can deliver economic value by helping doctors avoid prescribing costly but ineffective therapies, the field lacks literature testing that hypothesis. This session will highlight recent studies on the clinical and economic value of personalized medicine, shedding light on what we know about personalized medicine's clinical and economic utility — and what we don't.

**5:45 p.m.**  
**Elements Café Cocktail Reception**
"[We're] not talking about something that may happen someday. [We're] talking about what's happening now."

Howard McLeod, Pharm.D.
Medical Director, DeBartolo Family Personalized Medicine Institute, Moffitt Cancer Center

NOVEMBER 16, 2017

Joseph B. Martin Conference Center
Harvard Medical School
Boston, MA 02115
7:00 a.m. | Registration and Breakfast

8:00 a.m. | Opening Remarks
SPEAKER | Stephen L. Eck, M.D., Ph.D., President, CEO, Aravive Biologics; Board Chairman, PMC

8:10 a.m. | Clinical Adoption of Personalized Medicine: A Two-Part Discussion
Pioneering health care providers have begun to explore the business models, operational processes, IT infrastructure and educational programs that are needed to catalyze the paradigm shift toward personalized medicine. This two-part session on clinical adoption will examine the strategic and day-to-day challenges clinical organizations face as they seek to integrate personalized medicine in clinical settings — and the solutions they employ to address those challenges.

SESSION CHAIR | Marcia A. Kean, M.B.A., Chairman, Strategic Initiatives, Feinstein Kean Healthcare

8:15 A.M. | The Case for Personalized Medicine in the Clinic: The View From the Corner Office
Inspiring an organizational commitment to a new way of practicing medicine requires visionary leadership. This fireside chat will highlight the viewpoints and approaches of leaders who are spearheading efforts to adopt personalized medicine at clinical institutions, with an eye on the value proposition for changing existing norms and practices.

MODERATOR | Howard McLeod, Pharm.D., Medical Director, DeBartolo Family Personalized Medicine Institute, Moffitt Cancer Center
Jeffrey R. Balser, M.D., Ph.D., Dean of Vanderbilt University School of Medicine, President and CEO, Vanderbilt University Medical Center
Ronald A. Paulus, M.D., President and CEO, Mission Health

9:00 A.M. | Practicing Personalized Medicine: Lessons From the Front Lines
To successfully integrate personalized medicine into a health system, administrators and clinicians must also design and implement new processes related to program infrastructure and informatics; help educate physicians and patients about the field; and inspire cultural change within the institution. During this panel discussion, a group of early adopters will share lessons learned from implementing pilot programs across the United States.

MODERATOR | Daryl Pritchard, Ph.D., Vice President, Science Policy, Personalized Medicine Coalition
Bonnie J. Addario, Founder, Chair, Bonnie J. Addario Lung Cancer Foundation; Lung Cancer Survivor
Scott A. Beck, M.B.A., Administrator, Center for Individualized Medicine, Mayo Clinic
Timothy Cannon, M.D., Clinical Director, Molecular Tumor Board, Inova Schar Cancer Institute
Peter Hulick, M.D., M.M.Sc., Medical Director, Center for Personalized Medicine, NorthShore University HealthSystem
Marc S. Williams, M.D., Director, Genomic Medicine Institute, Geisinger

10:15 a.m. | Networking Break
(sponsored by Moffitt Cancer Center)
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Presenter/Introduction/Keynote</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:45 a.m.</td>
<td>Harvard Business School Case Study — Intermountain Healthcare: Pursuing Precision Medicine</td>
<td>Intermountain has a long history of being at the forefront of health care quality improvement and the development of treatment protocols. In 2013, Intermountain Precision Genomics (IPG) was started with Dr. Lincoln Nadauld as its Executive Director. IPG focused on stage 4 cancer patients and performed three distinct functions: genomic sequencing, interpretation of sequencing results with recommendations for precision therapies, and drug acquisition and reimbursement. A paper published in February 2017 reported that in addition to having a higher quality of life, patients who received the targeted therapies had progression-free survival rates of almost twice as long as other patients. The purpose of our case discussion will be to assess these efforts, to consider their broader applicability and to review IPG's plans for the future. PRESENTER</td>
</tr>
<tr>
<td>11:45 a.m.</td>
<td>Overview of the International Landscape for Personalized Medicine</td>
<td>PRESENTER</td>
</tr>
<tr>
<td>12:00 p.m.</td>
<td>Bag Lunch</td>
<td></td>
</tr>
<tr>
<td>1:00 p.m.</td>
<td>Personalized Medicine at FDA: An Inside Look at the Agency’s Priorities for the Field</td>
<td>INTRODUCTION</td>
</tr>
<tr>
<td></td>
<td></td>
<td>KEYNOTE</td>
</tr>
<tr>
<td>2:00 p.m.</td>
<td>The Patient Perspective on Personalized Medicine</td>
<td>INTRODUCTION</td>
</tr>
<tr>
<td></td>
<td></td>
<td>KEYNOTE</td>
</tr>
<tr>
<td>2:30 p.m.</td>
<td>Patient 2.0: Exploring the Future of Personalized Medicine</td>
<td>Many observers speculate that the coming wave of gene editing, gene therapy, direct-to-consumer genetic tests and the personalized use of wearables will change the psychology, sociology, economy and efficacy of health care. Informed by the previous panel discussions, this conversation will examine the future of personalized medicine and the merits of these emerging trends. MODERATOR</td>
</tr>
<tr>
<td>3:30 p.m.</td>
<td>Closing Remarks</td>
<td>SPEAKER</td>
</tr>
</tbody>
</table>
## Thank You to Our Sponsors

Sponsorship opportunities for the 13th Annual Personalized Medicine Conference are available. Please contact Mary Bordoni, Director, Membership & Development, at mbordoni@personalizedmedicinedecalition.org for details.

### DIAMOND
- Intermountain Precision Genomics
- PhRMA

### PLATINUM
- Roche
- Genentech

### GOLD
- Bristol-Myers Squibb

### SILVER
- INOVA
- medidata
- nanoString Technologies
- Pfizer
- SevenBridges

### BRONZE
- endo
- Foundation Medicine
- Genomic Health
- L.E.K.
- MERCK
- National Pharmaceutical Council
- PHILIPS
- Quest Diagnostics
- SLONEPARTNERS
- SomaLogic
- Veritas
- Vertex

### CONTRIBUTOR
- AstraZeneca
- BHT Foundation
- Partenon
- flatiron
- FOLEY
- FOLEY & LARDNER LLP
- Greybird Ventures
- Moffitt Cancer Center
- M2GEN

### MEDIA PARTNERS
- The CRISPR Journal
- Genome
- genomeweb
- Health 2.0
- STAT
- Washington Post